TY - JOUR
T1 - Microglia and brain macrophages in the molecular age
T2 - From origin to neuropsychiatric disease
AU - Prinz, Marco
AU - Priller, Josef
N1 - Funding Information:
The authors apologize to all of those colleagues whose work was discussed without proper quotation owing space constraints. The authors thank S. M. Brendecke for critically reading the manuscript and M. Knust for help with the artwork. M.P. and J.P. are joint coordinators of the DFG-funded research unit (FOR) 1336. In addition, M.P. is supported by the BMBF-funded competence network of multiple sclerosis (KKNMS), the Gemeinnützige Hertie-Stiftung (GHST), the Fritz Thyssen Stiftung, the competence network of neurodegenerative disorders (KNDD) and the DFG (SFB 992). J.P. receives additional funding from the DFG (SFB/TRR43 and the Cluster of Excellence NeuroCure), the BMBF (Forschungsnetz zu psychischen Erkrankungen) and the Berlin Institute of Health.
PY - 2014/5
Y1 - 2014/5
N2 - Mononuclear phagocytic cells in the CNS used to be defined according to their anatomical location and surface marker expression. Recently, this concept has been challenged by the results of developmental and gene expression profiling studies that have used novel molecular biological tools to unravel the origin of microglia and to define their role as specialized tissue macrophages with long lifespans. Here, we describe how these results have redefined microglia and helped us to understand how different myeloid cell populations operate in the CNS based on their cell-specific gene expression signatures, distinct ontogeny and differential functions. Moreover, we describe the vulnerability of microglia to dysfunction and propose that myelomonocytic cells might be used in the treatment of neurological and psychiatric disorders that are characterized by primary or secondary 'microgliopathy'.
AB - Mononuclear phagocytic cells in the CNS used to be defined according to their anatomical location and surface marker expression. Recently, this concept has been challenged by the results of developmental and gene expression profiling studies that have used novel molecular biological tools to unravel the origin of microglia and to define their role as specialized tissue macrophages with long lifespans. Here, we describe how these results have redefined microglia and helped us to understand how different myeloid cell populations operate in the CNS based on their cell-specific gene expression signatures, distinct ontogeny and differential functions. Moreover, we describe the vulnerability of microglia to dysfunction and propose that myelomonocytic cells might be used in the treatment of neurological and psychiatric disorders that are characterized by primary or secondary 'microgliopathy'.
UR - https://www.scopus.com/pages/publications/84899418705
U2 - 10.1038/nrn3722
DO - 10.1038/nrn3722
M3 - Review article
C2 - 24713688
AN - SCOPUS:84899418705
SN - 1471-003X
VL - 15
SP - 300
EP - 312
JO - Nature Reviews Neuroscience
JF - Nature Reviews Neuroscience
IS - 5
ER -